Kyverna Therapeutics KYTX
NASDAQ KYTX
$8.30 -0.05 (-0.60%)
As of: Sep 4, 2026 · 3:13 PM EDT

Kyverna Therapeutics (KYTX) Non Operating Interest Expenses (2023 - 2026)

Analysis

Kyverna Therapeutics (KYTX) Non Operating Interest Expenses (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Kyverna Therapeutics 506.05 Mn 506.05 Mn - 674,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 674,000.00
Mar 31, 2026 667,000.00
Dec 31, 2025 444,000.00
Sep 30, 2025 7,000.00
Jun 30, 2025 14,000.00
Mar 31, 2025 25,000.00
Dec 31, 2024 27,000.00
Sep 30, 2024 32,000.00
Jun 30, 2024 39,000.00
Mar 31, 2024 44,000.00
Dec 31, 2023 47,000.00
Sep 30, 2023 50,000.00
Jun 30, 2023 46,000.00
Mar 31, 2023 44,000.00